Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.
Purity:
95.00%
CAS Number:
[2377419-89-9]
Target:
PD-1/PD-L1|||HER|||EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
